Recruiting

Investigating a treatment for moderate-to-severe active thyroid eye disease

The purpose of this study is to evaluate the efficacy, safety and tolerability of subcutaneous teprotumumab in participants with moderate-to-severe active thyroid eye disease (TED). TED is an autoimmune disease in which the eye muscles and fatty tissue behind the eye become inflamed. This can push the eyes forward (bulging) or cause redness and swelling. Symptoms can range from mild to sight-threatening. Current treatment options for moderate/severe TED are not optimal (lots of side effects), but teprotumumab holds promise and is being tested for treatment of TED in this trial.

Status
Recruiting

Combined Radiotherapy and Intravenous Steroids for Early Progressive Thyroid Eye Disease (CRISEPTED)

Thyroid eye disease is an autoimmune disorder affecting approximately 50% of individuals with autoimmune thyroid diseases resulting in enlargement of ocular muscles and may lead to congestion of the eyelids and ocular surface, ocular movement restriction and double vision, and optic nerve compression and loss of vision.

First line medical therapy is oral or intravenous corticosteroids (CS), which several studies have shown results in reduction of soft tissue congestion, but some studies suggesting that ocular restriction or visual loss may still occur in spite of CS therapy.

Status
Recruiting
Subscribe to Thyroid